pharma letter lab workersThe Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the Pharmaceuticals, Biotechnology and Generics sectors of the overall health care industry, backed by a team of respected writers with many years of experience in the field.

Register for free for our daily email newsletter and  to get access to premium content for 7 days free!

Latest Pharma Letter Articles

Pharmaceutical

features_upload_img_2

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19 June 2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced

Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent

19 June 2013

USA-based Actavis (NYSE: ACT), itself predominantly a generic drug marketer, and Japan's Kissei

Biotechnology

features_upload_img_3

Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis

19 June 2013

Sweden-based Athera Biotechnologies, which is 65% owned by Karolinska Development, has entered

Genmab and ADC Thera link for antibody drug conjugate combining HuMax-TAC and PBD warhead

18 June 2013

Denmark's Genmab (OMX: GEN) and Switzerland-based ADC Therapeutics have entered an agreement

Generics

features_upload_img_4

Negative US patent ruling for Novo Nordisk on Prandin

19 June 2013

Denmark-based insulin giant Novo Nordisk (NOV: N) says that the US Court of Appeals for the

US Supreme Court says patent settlement can "sometimes" be illegal

18 June 2013

In a long awaited ruling in the USA, the US Supreme Court yesterday (June 17) ruled in the